Holen Sie sich die Stockscreener-App
14.16
1.58%
0.24
Schlusskurs vom Vortag:
$13.92
Offen:
$13.97
24-Stunden-Volumen:
45,493
Relative Volume:
0.09
Marktkapitalisierung:
$506.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+10.21%
1M Leistung:
+17.25%
6M Leistung:
+205.40%
1J Leistung:
+177.80%
1-Tages-Spanne:
$13.67
$14.39
1-Wochen-Bereich:
$11.87
$16.43
52-Wochen-Spanne:
$2.88
$16.43
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Vergleichen Sie BIOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
14.12 | 499.10M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
126.23 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.33 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.915 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.07 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
50.74 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
Aug Ideas: Will BioAge Labs Inc. stock maintain growth storyRate Hike & Target Return Focused Stock Picks - ulpravda.ru
How analysts rate BioAge Labs Inc. stock todayJuly 2025 News Drivers & Reliable Momentum Entry Alerts - ulpravda.ru
Is BioAge Labs Inc. (Y7G) stock included in top ETFs2025 Pullback Review & Low Drawdown Momentum Trade Ideas - ulpravda.ru
What MACD trends signal for BioAge Labs Inc. (Y7G) stockQuarterly Risk Review & Verified Swing Trading Watchlist - ulpravda.ru
Why BioAge Labs Inc. stock could outperform in 20252025 Volume Leaders & Reliable Volume Spike Trade Alerts - ulpravda.ru
Aug Selloffs: Will BioAge Labs Inc. stock gain from lower inflationWeekly Profit Analysis & Scalable Portfolio Growth Methods - ulpravda.ru
BioAge Labs Hits New 52-Week High; Next Key Catalyst Due In 1H 2026 - RTTNews
Can BioAge Labs Inc. stock deliver sustainable ROEQuarterly Earnings Review & Maximum Profit Growth - bollywoodhelpline.com
BioAge Labs upgraded to equal weight from underweight at Morgan Stanley - MSN
BIOA INVESTORS: Kirby McInerney LLP Reminds BioAge Labs, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm - TMX Newsfile
BioAge Labs (NASDAQ:BIOA) Sets New 52-Week HighStill a Buy? - MarketBeat
Cash per share of BioAge Labs, Inc. – FWB:Y7G - TradingView — Track All Markets
BioAge Labs, Inc.(NasdaqGS: BIOA) added to NASDAQ Biotechnology Index - marketscreener.com
BioAge Labs announces positive phase 1 trial results - MSN
BioAge Labs (BIOA) Price Target Increased by 24.14% to 12.24 - Nasdaq
Is BioAge Labs Inc. stock dividend yield sustainableJuly 2025 Catalysts & Real-Time Volume Trigger Notifications - Улправда
Can BioAge Labs Inc. stock continue upward trendMarket Activity Summary & Verified Momentum Stock Ideas - Улправда
Why BioAge Labs Inc. (Y7G) stock is listed among top recommendationsQuarterly Market Review & Risk Controlled Daily Trade Plans - DonanımHaber
What makes BioAge Labs Inc. stock attractive to growth fundsJuly 2025 Levels & Precise Swing Trade Alerts - DonanımHaber
Can BioAge Labs Inc. stock withstand economic slowdown2025 Technical Overview & Technical Confirmation Alerts - DonanımHaber
Bioage Labs Earnings Notes - Trefis
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Globe and Mail
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool
Bioage Labs Stock Rockets 52% With 8-Day Winning Streak - Trefis
Paul Rubin Sells 18,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
BioAge Labs CMO Paul D. Rubin Sells 18,000 Shares - TradingView — Track All Markets
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
Officer Rubin Files To Sell 18,000 Of BioAge Labs Inc [BIOA] - TradingView — Track All Markets
Morgan Stanley Upgrades BioAge Labs (BIOA) - Nasdaq
BioAge Labs (BIOA) Competitors and Alternatives 2025 - MarketBeat
Volume Recap: How BioAge Labs Inc stock reacts to Fed rate cutsFed Meeting & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Paul Rubin Sells 68,897 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen - MarketBeat
BioAge Labs CMO Paul D. Rubin Sells All Common Stock Holdings - TradingView
Officer Rubin Sells 68,897 ($701.9K) Of BioAge Labs Inc [BIOA] - TradingView
BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data - Investing.com South Africa
How BioAge Labs Inc. stock reacts to Fed rate cutsShort Setup & Fast Gain Stock Trading Tips - Newser
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial - Investing.com Nigeria
Is BioAge Labs Inc. stock a safe haven assetQuarterly Earnings Summary & Safe Entry Zone Identification - Newser
Why BioAge Labs Inc. stock remains undervaluedCEO Change & Smart Money Movement Alerts - Newser
How BioAge Labs Inc. (Y7G) stock stacks up against competitorsInsider Selling & Daily Chart Pattern Signal Reports - Newser
Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs - TipRanks
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioage Labs Inc-Aktie (BIOA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Jan 02 '26 |
Sale |
12.85 |
7,433 |
95,490 |
0 |
0.72%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):